drugset / Trial / NCT07419880
Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
RECLAIM: A Phase II, Open-Label, Single-Arm, Multicenter Clinical Trial of Cromolyn, TQB2102, and Panpulimab for Re-Challenging Immune-Refractory Triple-Negative Breast Cancer
Timeline
- Start
- 2026-01-30
- Primary completion
- 2027-01-30
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cromolyn | Small molecule | 10 mg | Intranasal |
| Subject | Panpulimab | Unknown | 200 mg | Intravenous |
| Subject | TQB2102 | Monoclonal antibody | 6 mg/kg | Intravenous |